Cejalvo María J, de la Rubia Javier
a 1 Hematology Service, University Hospital Doctor Peset, Valencia, Spain.
Expert Rev Hematol. 2015 Oct;8(5):595-611. doi: 10.1586/17474086.2015.1078236. Epub 2015 Sep 1.
The introduction of the novel agents, thalidomide, bortezomib and lenalidomide as part of the frontline induction both in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients' prognosis. Current treatment goals are aimed to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their quality of life. This article reviews the current landscape of frontline treatment both in transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma.
新型药物沙利度胺、硼替佐米和来那度胺作为一线诱导治疗方案的一部分，应用于适合移植和不适合移植的患者，显著提高了不同治疗方案的抗骨髓瘤疗效，改善了患者的预后。目前的治疗目标是在不增加毒性的情况下，进一步提高完全缓解率、疾病进展时间、无进展生存期和总生存期。此外，针对老年人群正在制定不同的策略，因为这类患者需要更密切的监测，并采用个体化、调整剂量的方案，以提高耐受性，同时维持他们的生活质量。本文综述了新诊断的多发性骨髓瘤患者中适合移植和不适合移植患者的一线治疗现状。
